MValve technologies
Mitral Regurgitation Solution
Company Overview
Snapshot
Founded in December 2011 by Assif Stoffman and Maurice Buchbinder, MValve technologies operated with 1–10 employees. The company secured funding across two rounds, attracting Boston Scientific. In October 2015, MValve Technologies successfully implanted its first human catheter-based mitral valve replacement system.
Business overview
MValve technologies is a Health Tech & Life Sciences company focused on developing solutions for mitral regurgitation, a condition characterized by the abnormal reversal of blood flow within the heart. The company's core product, Lotus, is a catheter-based mitral valve replacement system designed to address this cardiovascular issue. MValve technologies operates within the medical devices, life support, and medical treatment & therapeutics sectors, primarily serving healthcare providers in markets such as the United States.
Strategic signal
In October 2015, MValve Technologies achieved a significant milestone by implanting its first human catheter-based mitral valve replacement system. This event signals critical progress in the clinical development and validation of its technology, demonstrating the potential for its solution to address mitral regurgitation and advance cardiac care. For investors, this represents a key de-risking event and a step towards commercial viability in the medical device market.
Log in to access full profile ›Company Intelligence Q&A
- What is MValve technologies' primary focus?
- MValve technologies is dedicated to providing a solution for mitral regurgitation, an abnormal reversal of blood flow from the heart's left ventricle to the left atrium.
- When was MValve technologies founded?
- MValve technologies was founded in December 2011.
- What was a significant clinical milestone for MValve technologies?
- In October 2015, MValve Technologies successfully implanted its first human catheter-based mitral valve replacement system.
- Which company backed MValve technologies in July 2014?
- In July 2014, Boston Scientific backed MValve technologies.
- What is the status of MValve technologies?
- MValve technologies is Non Active and ceased to operate in October 2018.